<DOC>
	<DOCNO>NCT00872781</DOCNO>
	<brief_summary>The study conduct open-label , balance , randomize , two-treatment , two-period , two-sequence , single-dose , crossover , bioavailability study compare Quinapril hydrochloride Hydrochlorothiazide tablets 20 mg/25 mg OHM Laboratories Inc ( subsidiary Ranbaxy pharmaceutical Inc ) AccureticTM tablets 20 mg/ 25 mg ( contain quinapril hydrochloride 20 mg hydrochlorothiazide 25 mg ) manufacture Parke Davis Pharmaceuticals Limited , Vega Baja , PR 00694 , Made Germany distribute Parke-Davis , Division Pfizer Inc. NY , NY 10017 healthy , adult , male , human subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Quinapril Hydrochloride 20 mg Hydrochlorothiazide 25 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Following overnight fast least 10 hour , single oral dose Quinapril hydrochloride Hydrochlorothiazide tablets 20 mg/25 mg AccureticTM tablet 20 mg/ 25 mg ( contain quinapril hydrochloride 20 mg hydrochlorothiazide 25 mg ) administer period study , along 240 mL drink water ambient temperature low light condition supervision train study personnel . A total sixty-four ( 64 ) subject enrol study . One subject ( subject number 18 ) drop study two subject ( subject number 47 50 ) withdrawn study . Hence Sixty-one ( 61 ) subject complete period study . For Quinapril Hydrochlorothiazide pharmacokinetic statistical analysis perform data 61 subject complete period study .</detailed_description>
	<mesh_term>Quinapril</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>1 . Were age range 1845 year . 2 . Were neither overweight underweight correspond height per Life Insurance Corporation India height/weight chart nonmedical case . 3 . Had voluntarily give write informed consent participate study . 4 . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . 1 . History allergy quinapril , hydrochlorothiazide , sulfonamide derive drug related ACE inhibitor . 2 . Subject sit systolic blood pressure le 90 mmHg &gt; 140 mmHg diastolic blood pressure le 60 mmHg &gt; 90 mm Hg day admission . 3 . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . 4 . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . 5 . Presence value significantly different normal reference range and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . 6 . Positive urinary screen test drug abuse ( opiates cannabinoids ) 7 . Presence value significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . 8 . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , epithelial cell ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . 9 . Clinically abnormal ECG Chest Xray . 10 . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes glaucoma . 11 . History psychiatric illness might impair ability provide write informed consent . 12 . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . 13 . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . 14 . Used enzyme modify drug within 30 day prior Day 1 study . 15 . Participated clinical trial within 12 week precede Day 1 study . 16 . Subjects , completion study , donate and/or lose 350 mL blood past 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Bioequivalence fix dose combination Quinapril HCl 20 mg Hydrochlorothiazide 25 mg tablet</keyword>
</DOC>